Table I.
Attribute | Patient group (%) |
p-value* | ||
---|---|---|---|---|
Patients group (%) | Low MPV/PC (MPV/PC < 0.06) | High MPV/PC (MPV/PC ≥ 0.06) | ||
Patients (%) | 45 (100%) | 36 (80) | 9 (20) | |
Age | 0.898 | |||
Median [IQR] | 76 [68–81] | 76 [66.8–81] | 76 [72–79] | |
Min–max | 53–86 | 53–86 | 62–84 | |
Sex | 1.00 | |||
Male | 33 (73.3) | 26 (72.2) | 7 (77.8) | |
Female | 12 (26.7) | 10 (27.8) | 2 (22.2) | |
ECOG-PS score | 1.00 | |||
0–1 | 41 (91.1) | 33 (91.7) | 8 (88.9) | |
2–4 | 4 (8.9) | 3 (8.3) | 1 (11.1) | |
Primary site | 1.00 | |||
Head | 43 (95.6) | 34 (93.8) | 9 (100) | |
Face | 2 (4.4) | 2 (6.3) | 0 (0) | |
Tumour size | 0.482 | |||
< 5cm | 25 (55.6) | 21 (58.3) | 4 (44.4) | |
≥ 5cm | 20 (44.4) | 15 (41.7) | 5 (55.6) | |
Number of skin lesions | 0.712 | |||
Single | 19 (42.2) | 16 (44.4) | 3 (33.3) | |
Multiple | 26 (57.8) | 20 (55.6) | 6 (66.7) | |
Lymph node metastasis | 0.173 | |||
Absent | 41 (91.1) | 34 (93.8) | 7 (77.8) | |
Present | 4 (8.9) | 2 (6.3) | 2 (22.2) | |
Distant metastasis | 0.173 | |||
Absent | 41 (91.1) | 34 (93.8) | 7 (77.8) | |
Present | 4 (8.9) | 2 (6.3) | 2 (22.2) | |
1st line chemotherapy | 1.00 | |||
Paclitaxel | 32 (71.1) | 25 (69.4) | 7 (77.8) | |
Docetaxel | 2 (4.4) | 2 (5.6) | 0 (0) | |
Interleukin-2 | 11 (24.4) | 9 (2.5) | 2 (22.2) | |
Surgery for ASHN | 0.086 | |||
Absent | 33 (73.3) | 24 (66.7) | 9 (100) | |
Present | 12 (26.7) | 12 (33.3) | 0 (0) | |
Radiation for ASHN | 1.00 | |||
Absent | 12 (26.7) | 10 (27.8) | 2 (22.2) | |
Present | 33 (73.3) | 26 (72.2) | 7 (77.8) | |
Outcome | 1.00 | |||
Alive | 21 (46.7) | 17 (47.2) | 4 (44.4) | |
Dead | 24 (53.3) | 19 (52.8) | 5 (55.6) |
ASHN: angiosarcoma of the head and neck; ECOG-PS: Eastern Cooperative Oncology Group performance; IQR: interquartile range; MPV: mean platelet volume; PC: platelet count.
Statistically significant: p < 0.05.